CL2017002153A1 - Compuestos bicíclicos de sulfonamida cetona - Google Patents
Compuestos bicíclicos de sulfonamida cetonaInfo
- Publication number
- CL2017002153A1 CL2017002153A1 CL2017002153A CL2017002153A CL2017002153A1 CL 2017002153 A1 CL2017002153 A1 CL 2017002153A1 CL 2017002153 A CL2017002153 A CL 2017002153A CL 2017002153 A CL2017002153 A CL 2017002153A CL 2017002153 A1 CL2017002153 A1 CL 2017002153A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- ketone compounds
- present
- bicyclic sulfonamide
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
<p>La presente invención proporciona compuestos de la Fórmula (I), en donde: como se define en la especificación, un enantiómero, diaestereómero, atropisómero del mismo, o una mezcla de los mismos, o sales farmacéuticamente aceptables de los mismos, que son inhibidores de los canales de sodio regulados por voltaje, en particular Nav 1.7. Los compuestos son útiles para el tratamiento de enfermedades que se tratan por la inhibición de canales de sodio tales como trastornos de dolor, tos, o comezón. También se proporcionan composiciones farmacéuticas que contienen los compuestos de la presente invención.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127206P | 2015-03-02 | 2015-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002153A1 true CL2017002153A1 (es) | 2018-03-16 |
Family
ID=55543087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002153A CL2017002153A1 (es) | 2015-03-02 | 2017-08-24 | Compuestos bicíclicos de sulfonamida cetona |
Country Status (27)
Country | Link |
---|---|
US (1) | US10472356B2 (es) |
EP (1) | EP3265465B1 (es) |
JP (1) | JP6742331B2 (es) |
KR (1) | KR102649836B1 (es) |
CN (1) | CN107531705B (es) |
AR (1) | AR103833A1 (es) |
AU (1) | AU2016226340B2 (es) |
BR (1) | BR112017018755B1 (es) |
CA (1) | CA2978569C (es) |
CL (1) | CL2017002153A1 (es) |
CO (1) | CO2017009614A2 (es) |
CR (1) | CR20170392A (es) |
EA (1) | EA032928B1 (es) |
ES (1) | ES2728759T3 (es) |
HK (1) | HK1248687B (es) |
IL (1) | IL254161B (es) |
JO (1) | JO3595B1 (es) |
MX (1) | MX2017011042A (es) |
MY (1) | MY188700A (es) |
NZ (1) | NZ734888A (es) |
PE (1) | PE20180030A1 (es) |
PH (1) | PH12017501570A1 (es) |
SG (1) | SG11201707000UA (es) |
TN (1) | TN2017000376A1 (es) |
TW (1) | TWI700282B (es) |
UY (1) | UY36573A (es) |
WO (1) | WO2016141035A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
CN107991409B (zh) * | 2017-11-28 | 2020-04-24 | 中国医学科学院肿瘤医院 | 采用高效合相色谱同时测定血浆中12种磺胺类药物的方法 |
US10947251B2 (en) * | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
WO2020199683A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海海雁医药科技有限公司 | 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
US11319960B2 (en) * | 2020-09-03 | 2022-05-03 | Shenzhen Lanhe Technologies Co., Ltd. | Portable temperature regulation device |
CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
EP4347584A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
AU2022286511A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
EP4346818A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205778A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4620007A (en) * | 1980-09-03 | 1986-10-28 | Bayer Aktiengesellschaft | 6-fluoro-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid |
CN1894222A (zh) * | 2003-08-05 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 作为电压门控离子通道抑制剂的稠合嘧啶化合物 |
DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2011103715A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
AU2012328561A1 (en) * | 2011-10-28 | 2014-04-17 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
US9776995B2 (en) * | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-03-02 CR CR20170392A patent/CR20170392A/es unknown
- 2016-03-02 PE PE2017001464A patent/PE20180030A1/es unknown
- 2016-03-02 MX MX2017011042A patent/MX2017011042A/es active IP Right Grant
- 2016-03-02 MY MYPI2017001273A patent/MY188700A/en unknown
- 2016-03-02 AR ARP160100551A patent/AR103833A1/es unknown
- 2016-03-02 EA EA201791941A patent/EA032928B1/ru not_active IP Right Cessation
- 2016-03-02 ES ES16710566T patent/ES2728759T3/es active Active
- 2016-03-02 BR BR112017018755-8A patent/BR112017018755B1/pt active IP Right Grant
- 2016-03-02 JO JOP/2016/0032A patent/JO3595B1/ar active
- 2016-03-02 WO PCT/US2016/020403 patent/WO2016141035A1/en active Application Filing
- 2016-03-02 CN CN201680024836.2A patent/CN107531705B/zh active Active
- 2016-03-02 CA CA2978569A patent/CA2978569C/en active Active
- 2016-03-02 US US15/554,801 patent/US10472356B2/en active Active
- 2016-03-02 SG SG11201707000UA patent/SG11201707000UA/en unknown
- 2016-03-02 NZ NZ734888A patent/NZ734888A/en unknown
- 2016-03-02 KR KR1020177027941A patent/KR102649836B1/ko active IP Right Grant
- 2016-03-02 TW TW105106422A patent/TWI700282B/zh active
- 2016-03-02 TN TNP/2017/000376A patent/TN2017000376A1/en unknown
- 2016-03-02 EP EP16710566.7A patent/EP3265465B1/en active Active
- 2016-03-02 AU AU2016226340A patent/AU2016226340B2/en active Active
- 2016-03-02 UY UY0001036573A patent/UY36573A/es unknown
- 2016-03-02 JP JP2017546195A patent/JP6742331B2/ja active Active
-
2017
- 2017-08-24 CL CL2017002153A patent/CL2017002153A1/es unknown
- 2017-08-27 IL IL254161A patent/IL254161B/en active IP Right Grant
- 2017-08-31 PH PH12017501570A patent/PH12017501570A1/en unknown
- 2017-09-22 CO CONC2017/0009614A patent/CO2017009614A2/es unknown
-
2018
- 2018-06-26 HK HK18108233.0A patent/HK1248687B/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002153A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
UY37205A (es) | Inhibidores de bromodominios | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
EA201992299A1 (ru) | Соединения на основе ингибиторов ask1 и их применение | |
DOP2013000263A (es) | Compuestos de 2- (2,4,5-anilino sustituido) pirimidina derivados como moduladores de egfr utilizados para el tratamiento del cáncer | |
DOP2014000265A (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
EA201791327A1 (ru) | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида | |
AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
UY36123A (es) | Derivados de carboxamida | |
CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
CL2020001089A1 (es) | Compuestos inhibidores de tirosina cinasa de bruton (btk). | |
AR111416A2 (es) | Compuesto terapéutico para el dolor y síntesis del compuesto | |
EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |